FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...
Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise ...
Philadelphia, March 27, 2025 – Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), ...
This research collaboration aims to generate clinical evidence across a range of cancer types to support the implementation of Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology for tumor-informed ...
Countable Labs, achieved CE marking for its Countable 4 Platform, a single-molecule PCR instrument for molecular quantification featuring Countable PCR technology. The platform is ideal for any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results